Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 10/20 | 0.50 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.48 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15816623 | 0.81 | ALDH1A1 (0.55) | ERCC1ERCC4GAAKDM4EGLA | |
| SCHEMBL15840861 | 0.80 | ERCC1 (0.43) | NR4A2ERCC1ERCC4CHEK1CREBBP | |
| SCHEMBL26084077 | 0.80 | DAO (0.50) | NR4A2CREBBPGAAKDM4EGLA | |
| SCHEMBL15837010 | 0.79 | ERCC1 (0.53) | NR4A2ERCC1ERCC4CREBBPGAA | |
| SCHEMBL18584962 | 0.79 | CREBBP (0.61) | ERCC1ERCC4CREBBPGAAKDM4E | |
| SCHEMBL1553082 | 0.79 | PKM (0.47) | NR4A2CREBBPGAAKDM4EGLA | |
| SCHEMBL3355140 | 0.79 | DYRK1A (0.62) | NR4A2CHEK1CREBBPGAAKDM4E | |
| SCHEMBL4725368 | 0.77 | DYRK1A (0.60) | ERCC1ERCC4CREBBPGAAKDM4E | |
| SCHEMBL19182268 | 0.77 | ERCC1 (0.43) | NR4A2ERCC1ERCC4CHEK1CREBBP | |
| SCHEMBL14044622 | 0.76 | NR4A2 (0.41) | NR4A2CREBBPGAAKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4573085-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS | Glenmark Pharmaceuticals Limited (IN) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025076299-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119546587-A | Substituted pyridone compounds as CBL-B inhibitors | 格兰玛克制药有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-3762392-B1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO LTD (KR) | 2024-05-15 | — | — | EP | disclosed |
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240150325-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS | LG CHEM, LTD. (KR) | 2024-05-09 | — | — | US | disclosed |
| WO-2024038378-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS | GLENMARK PHARMACEUTICALS LTD (IN) | 2024-02-22 | — | — | WO | disclosed |
| EP-4284804-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | Schrödinger, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-101061098-A | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-24 | — | — | CN | disclosed |
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | Janssen Pharmaceuticals, Inc. | 2007-09-13 | — | — | US | disclosed |
| EP-1799646-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006116713-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006030032-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | WO | disclosed |
| EP-0265126-B1 | Process for the preparation of fused pyridine compounds | UNIV PRINCETON (US) | 1994-04-13 | — | — | EP | disclosed |
| US-4988813-A | Process for the preparation of fused pyridine compounds | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1991-01-29 | — | — | US | disclosed |
| US-4902796-A | 6-alkenyl and ethynyl derivatives of 2-amino-4-hydroxypyrido[2,3-d]pyrimidines | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1990-02-20 | — | — | US | disclosed |
| US-4818819-A | Process for the preparation of fused pyridine compounds | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1989-04-04 | — | — | US | disclosed |
| EP-0265126-A2 | Process for the preparation of fused pyridine compounds | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1988-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150325-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS | MAP3K20, SBK3, MAPKAPK2 | NR4A2 3149/4885ERCC1 2928/4885ERCC4 2893/4885 |
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | MALT1, LITAF, IL2 | NR4A2 2111/4885ERCC1 1177/4885ERCC4 1109/4885 |
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRM3 | NR4A2 167/4885ERCC1 4154/4885ERCC4 4561/4885 |
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBLC, CBL | NR4A2 2106/4885ERCC1 975/4885ERCC4 3575/4885 |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | NR4A2 1182/4885ERCC1 3866/4885ERCC4 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.